Franklin Biolabs is a fully integrated preclinical CRO built to advance complex cell and gene therapies for CNS disorders from discovery through IND-enabling studies. Headquartered in Philadelphia, Franklin brings deep experience developing genetic medicine, including programs targeting a range of neurologic and systemic diseases. Franklin Biolabs’ in vivo team supports CNS-focused development with specialized animal models, diverse routes of administration, including intraparenchymal, intracerebroventricular (ICV), and intracisternal delivery, and detailed neurobehavioral and motor function assessments that capture meaningful functional outcomes.

Franklin’s platform incorporates advanced safety readouts such as nerve conduction studies, as well as imaging modalities including MRI and fluoroscope-guided procedures, and biomarkers. Building on extensive experience with CSF-delivery for multiple CNS indications, Franklin designs and executes pharmacology and GLP and non‑GLP toxicology studies that address biodistribution, on‑ and off‑target effects, and long‑term safety in relevant species. Franklin also offers in-house histopathology services that allow the ability to perform multiplex ISH/IF staining along with the standard H&E for safety readouts. With integrated bioanalytical, imaging, and in vivo capabilities, Franklin Biolabs provides end‑to‑end support to de‑risk CNS pipelines and accelerate transformative genetic medicines to patients worldwide.